These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 15272921

  • 1. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW, Rhee EJ, Lee WY, Kim SW, Oh ES, Baek KH, Kang MI, Choi MG, Yoo HJ, Park SW.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [Abstract] [Full Text] [Related]

  • 2. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

  • 3. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Mar; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 4. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Mar; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 5. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
    Dai Y, Shen L.
    Chin Med J (Engl); 2007 Nov 20; 120(22):2017-21. PubMed ID: 18067789
    [Abstract] [Full Text] [Related]

  • 6. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R.
    J Clin Endocrinol Metab; 2002 Oct 20; 87(10):4470-5. PubMed ID: 12364420
    [Abstract] [Full Text] [Related]

  • 7. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
    Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW.
    Am J Obstet Gynecol; 2005 Apr 20; 192(4):1087-93. PubMed ID: 15846185
    [Abstract] [Full Text] [Related]

  • 8. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Apr 20; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 9. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr 20; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 10. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.
    Metabolism; 2007 May 20; 56(5):699-707. PubMed ID: 17445547
    [Abstract] [Full Text] [Related]

  • 11. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A, Prenner G, Kniepeiss D, Iberer F, Tscheliessnigg KH, Piswanger-Sölkner C, Obermayer-Pietsch B, Leb G, Dobnig H.
    Wien Klin Wochenschr; 2002 Aug 30; 114(15-16):717-24. PubMed ID: 12602117
    [Abstract] [Full Text] [Related]

  • 12. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
    Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y.
    J Bone Miner Res; 1999 Apr 30; 14(4):518-27. PubMed ID: 10234572
    [Abstract] [Full Text] [Related]

  • 13. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA, Malaponte G, Pennisi P, Li Volti G, Trovato G, Mangiafico M, Bevelacqua Y, Mazza F, Fiore CE.
    J Intern Med; 2007 Jun 30; 261(6):587-96. PubMed ID: 17547714
    [Abstract] [Full Text] [Related]

  • 14. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C.
    Bone; 2004 Sep 30; 35(3):785-91. PubMed ID: 15336617
    [Abstract] [Full Text] [Related]

  • 15. [Serum osteoprotegrin and serum bone gamma-carboxyglutamine acid-containing protein are correlated with bone mineral density in normal women].
    Fang TY, Liao EY, Wu XP, Liu SP, Xie H, Zhang H, Luo XH, Cao XZ.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 02; 84(19):1607-9. PubMed ID: 15569454
    [Abstract] [Full Text] [Related]

  • 16. Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women.
    Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, Irahara M.
    Menopause; 2008 Oct 02; 15(1):180-4. PubMed ID: 17545921
    [Abstract] [Full Text] [Related]

  • 17. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Oct 02; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 18. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Oct 02; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 19. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Oct 02; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 20. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang LZ, Xu MY, Chen JL.
    Zhonghua Nei Ke Za Zhi; 2004 Jun 02; 43(6):447-50. PubMed ID: 15312444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.